Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.
Dendritic cells (DCs) are potent inducers of adaptive immunity and their clinical use in cancer vaccine formulations remains an area of active translational and clinical investigation. Although cancer vaccines applied as monotherapies have had a modest history of clinical success, there is great enthusiasm for novel therapeutic strategies combining DC-based cancer vaccines with agents that 'normalize' immune function in the tumor microenvironment (TME). Broadly, these combination vaccines are designed to antagonize/remove immunosuppressive networks within the TME that serve to limit the antitumor action of vaccine-induced T cells and/or to condition the TME to facilitate the recruitment and optimal function and durability of vaccine-induced T cells. Such combination regimens are expected to dramatically enhance the clinical potency of DC-based cancer vaccine platforms.
Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Ronald J
RJ
Fecek
Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.|Department of Immunology, University of Pittsburgh School of Medicine, PA, USA.|Department of Pathology, University of Pittsburgh School of Medicine, PA, USA.|Department of Bioengineering, University of Pittsburgh School of Medicine, PA, USA.|University of Pittsburgh Cancer Institute, PA, USA.
Walter J
WJ
Storkus
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000276:immunology*; D003131:Combined Modality Therapy; D061025:Costimulatory and Inhibitory T-Cell Receptors / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation*; D053450:Glucocorticoid-Induced TNFR-Related Protein / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008213:Lymphocyte Activation; D009000:Monocytes / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*; D059016:Tumor Microenvironment
D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D061025:Costimulatory and Inhibitory T-Cell Receptors; D053450:Glucocorticoid-Induced TNFR-Related Protein; C491405:TNFRSF18 protein, human
cancer; combination immunotherapy; dendritic cell; immunoconditioning; immunoregulation; targeted therapy; vaccine